New COVID subvariant is now dominant across the U.S., accounting for 43% of all new cases in latest week, CDC says
admin The XBB.1.5 omicron subvariant that has been dominant in the Northeast for several weeks is…
Read MoreBiotechnology
COVID subvariant dominant in northeastern U.S. has a growth advantage and may have greater ability to evade immunity than earlier strains, WHO says
The XBB.1.5 omicron subvariant has a growth advantage over other circulating subvariants of the virus…
Read MoreChina stops issuing visas to Japanese and South Korean visitors as spat over test mandates for Chinese tourists widens
China stopped issuing visas for visitors from Japan and South Korea on Tuesday in apparent…
Read MoreChina takes first steps to punish countries that imposed testing mandates for Chinese travelers
China on Tuesday suspended visas for South Koreans to enter the country for tourism or…
Read MoreModerna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government’s pandemic response
A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday,…
Read MoreOcugen stock up 16% premarket after company announced positive results for its COVID vaccine
Ocugen Inc. stock OCGN, +0.78% rallied 16% in premarket trade Monday, after the biopharma company…
Read MoreChina’s latest COVID challenge: Lunar New Year holiday travel surge
China is hoping to avoid an acceleration in the pace of new COVID cases during…
Read MoreWHO is ‘concerned’ about coronavirus variant XBB.1.5 and its apparent growth advantage
The global tally of COVID cases rose 25% in the period stretching from Dec. 5…
Read MoreAs EU works to coordinate response to China’s COVID wave, Beijing and airlines are unhappy
European Union officials were working Wednesday to coordinate a response to China’s current surge of…
Read MoreNew omicron subvariant has become dominant in U.S., climbing to about 41% of cases from 1.3% at the start of December
XBB.1.5 accounted for 40.5% of all cases in the week through Dec. 31, outstripping the…
Read More